RxDoctor Payments Data

Mary Boyle

Nurse Practitioner · Scottsdale, AZNPI 1861475113

Payments from drug & device makers

$1,254in general payments, 2019–2025

Across 13 payments — averaging $96.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tandem Diabetes Care, Inc.$370
  • Dexcom, Inc.$216
  • Medtronic$190
  • Kyowa Kirin, Inc.$125
  • Abbott$124
  • Sanofi-aventis U.S. LLC$86
  • plus $144 from 3 others

What the payments were for

  • Food & beverage$1,254100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,254 in reported general payments places this provider in the 80th percentile of 1,719 nurse practitioner providers in Arizona.

See all nurse practitioner providers in Arizona

Medicare billing

Part B allowed, 2024
$472,227
Medicare patients
486
Services billed
32,770

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide150$195,698
OzempicSemaglutide108$137,705
TrulicityDulaglutide51$60,452
JardianceEmpagliflozin56$59,737
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/732$56,270
FarxigaDapagliflozin Propanediol39$36,939
Fiasp FlextouchInsulin Aspart (Niacinamide)29$31,332
Humalog Kwikpen U-100Insulin Lispro95$29,952
Lantus SolostarInsulin Glargine,hum.Rec.Anlog183$24,673
Tresiba Flextouch U-100Insulin Degludec35$23,946
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog46$16,614
HumalogInsulin Lispro37$13,817
Novolog FlexpenInsulin Aspart56$12,803
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$11,686
FiaspInsulin Aspart (Niacinamide)14$10,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Fiasp, Novolog$74$153,368135 claims
Boehringer IngelheimJardiance$48$59,73756 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,719 nurse practitioner providers in Arizona.

Other nurse practitioner in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →